Does Dayvigo help people fall asleep and stay asleep?
1,006 adults aged 55–88 with insomnia. Lemborexant 5 or 10 mg, zolpidem extended release 6.25 mg, or placebo at bedtime for one month.
Both lemborexant doses improved the primary sleep-onset measure versus placebo. Secondary overnight wake time improved by 24.0 and 25.4 minutes versus placebo. Second-half-of-night wake time improved by 6.7 and 8.0 minutes versus zolpidem.
One-month trial, predominantly women. No treatment-related serious adverse events were reported; most other events were mild or moderate. These results do not establish benefit in people without insomnia.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
One-month trial, predominantly women. No treatment-related serious adverse events were reported; most other events were mild or moderate. These results do not establish benefit in people without insomnia.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.